|Abstract:|| A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurized canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimizing the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.|
|Inventor(s):|| Wright; David Dakin Iorwerth (Buckinghamshire, GB), Harman; Anthony David (Oxfordshire, GB), Robinson; Nikki (Uxbridge, GB), Hodges; Garry (Middlesex, GB), Kadar; Adil (Middlesex, GB), Moggridge; Geoffrey D. (Cambridge, GB), Van Liew; Hugh (Bamstable, MA) |
|Assignee:|| BTG International Ltd. (London, GB) |
1. A foam comprising a liquid phase and a gas phase wherein the foam is obtained by mixing the liquid phase and gas phase and wherein the liquid phase comprises at
least one sclerosing agent and the gas phase consists essentially of 0.01% to 0.8% vol/vol nitrogen, 10 to 90% vol/vol carbon dioxide, and the remaining gas oxygen.
2. The foam of claim 1, wherein the nitrogen is present in an amount ranging from 0.01% to 0.7%.
3. The foam of claim 1, wherein the nitrogen is present in an amount ranging from 0.01% to 0.6%.
4. The foam of claim 1, wherein the at least one sclerosing agent is chosen from polidocanol, glycerol, sodium tetradecyl sulfate, or a mixture thereof.
5. The foam of claim 1, wherein the at least one sclerosing agent is polidocanol.
6. The foam of claim 5, wherein polidocanol is present in a concentration ranging from 0.5 to 4% vol/vol of the liquid phase.